MEDTRONIC 'BUY'

Analyst Glenn Novoarro of Banc of America Securities maintains his "buy" rating on Medtronic. The target price is set to $62. In a research note published this morning, the analyst mentions that the pivotal drug-eluting stent trial data for Endeavor III is expected to be released on Oct. 17.
Newratings